Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
Mayo Clinic · with National Cancer Institute (NCI) · NCT05557877
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–45 · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 2
- Target enrollment
- 60
- US sites recruiting
- 4
- Study start
- March 9, 2023
- Record last updated
- October 1, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.
Being studied: Biospecimen Collection; Low-Dose Aspirin; Questionnaire Administration; Biopsy
Conditions: Breast Carcinoma
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- PRE-REGISTRATION: Age >= 18 years and =\< 45 years of age
- PRE-REGISTRATION: Willingness to provide mandatory tissue specimens for correlative research at two timepoints.
- PRE-REGISTRATION: Had a live birth =\< 10 years prior to pre-registration
- PRE-REGISTRATION: Pre-menopausal according to patient report and/or clinical determination
- PRE-REGISTRATION: Provide written informed consent
- PRE-REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance
- PRE-REGISTRATION: Willingness to provide mandatory blood and urine specimens for correlative research
- REGISTRATION: Age >= 18 years and =\< 45 years of age
- REGISTRATION: Registration for this study must be completed either =\< one (1) year after the qualifying pre-registration biopsy is performed for this study or =\< one (1) year after collection of the archived tissue (for those who did not have a pre-registration biopsy performed after pre-registration for this study)
- REGISTRATION: Hemoglobin >= 9.0 g/dL (obtained =\< 90 days prior to registration)
- REGISTRATION: Platelet count >= 100,000/mm\^3 (obtained =\< 90 days prior to registration
- REGISTRATION: Serum creatinine =\< 2.0 mg/dl (obtained =\< 90 days prior to registration)
- REGISTRATION: Negative pregnancy test done =\< 15 days prior to registration
- REGISTRATION: Willing to use contraception while on treatment
- REGISTRATION: Provide written informed consent
- REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance
- REGISTRATION: Willingness to provide mandatory blood and urine specimens for correlative research
- REGISTRATION: Willingness to provide mandatory tissue specimens for correlative research
- REGISTRATION: Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Exclusion Criteria
- PRE-REGISTRATION: History of breast cancer including ductal breast carcinoma in situ (DCIS)
- PRE-REGISTRATION: Received systemic treatment for any other cancer at any time
- PRE-REGISTRATION: Currently taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDS) (no doses within =\< 5 days prior to pre-registration and no more than four doses within =\< 30 days prior to pre-registration)
- PRE-REGISTRATION: Currently taking other agents for the prevention of breast cancer
- PRE-REGISTRATION: Currently taking anticoagulants
- PRE-REGISTRATION: Contraindication for aspirin use
- PRE-REGISTRATION: Known or suspected active breast infection
- REGISTRATION: Known DCIS or invasive cancer
- REGISTRATION: No research tissue available from pre-registration biopsy or from archived tissue (collected =\< 12 months prior to pre-registration)
- REGISTRATION: Currently taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) (NOTE: no doses within =\< 5 days prior to registration and no more than four doses within =\< 30 days prior to registration)
- REGISTRATION: Co-morbid illnesses/conditions which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- REGISTRATION: Any contraindication to aspirin use including but not limited to:
- Bleeding disorders (e.g., hemophilia)
- Stomach or intestinal bleeding =\< 6 months prior to registration
- Known allergy to other non-steroidal anti-inflammatory drugs (NSAIDs)
- REGISTRATION: Currently taking anticoagulants
- REGISTRATION: Any prior or current malignancy requiring prior or current systemic therapy
- REGISTRATION: Currently pregnant or planning to become pregnant in the next 90 days
- REGISTRATION: Post-menopausal:
- Prior bilateral surgical oophorectomy or
- No menses for > 1 year with estradiol levels within postmenopausal range, according to institutional standard
- REGISTRATION: Known or suspected active breast infection
Recruiting US locations
Mayo Clinic in Florida
Jacksonville, FL 32224-9980
Site contact: Clinical Trials Referral Office · 855-776-0015 · mayocliniccancerstudies@mayo.edu
Indiana University Simon Comprehensive Cancer Center
Indianapolis, IN 46202
Site contact: Jessica M · 317-278-6706 · jlm41@iu.edu
Mayo Clinic in Rochester
Rochester, MN 55905
Site contact: Clinical Trials Referral Office · 855-776-0015 · mayocliniccancerstudies@mayo.edu
University of North Carolina
Chapel Hill, NC 27599
Site contact: Ana Gallegos · 919-966-4432 · Ana_Gallegos@med.unc.edu
Study contacts (from the official record)
- Clinical Trials Referral Office · 855-776-0015 · mayocliniccancerstudies@mayo.edu
Similar studies in Florida
All pregnancy studies in Florida →- RecruitingHealthy volunteersPhase 3
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
Pfizer
- Location
- North Miami Beach, FL + 76 other US sites
- Eligibility basics
- Ages 0 mo+
- RecruitingHealthy volunteersPhase 3
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
Pfizer
- Location
- Margate, FL + 111 other US sites
- Eligibility basics
- Ages 0 mo–49
- RecruitingHealthy volunteers
This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay…
American Laboratory Products Company
- Location
- North Miami, FL + 5 other US sites
- Eligibility basics
- Ages 13+
- RecruitingPhase 3
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
Aerogen Pharma Limited
- Location
- Jacksonville, FL + 17 other US sites
- Eligibility basics
- Any age listed